Esperion Therapeutics, Inc.
ESPR
$3.14
-$0.01-0.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 80.10M | 168.45M | 87.31M | 82.39M | 65.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 80.10M | 168.45M | 87.31M | 82.39M | 65.00M |
| Cost of Revenue | 34.57M | 41.78M | 55.42M | 35.78M | 44.10M |
| Gross Profit | 45.53M | 126.67M | 31.89M | 46.60M | 20.90M |
| SG&A Expenses | 43.12M | 41.43M | 41.85M | 39.51M | 43.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.69M | 83.21M | 97.27M | 75.29M | 87.09M |
| Operating Income | -6.58M | 85.23M | -9.96M | 7.10M | -22.10M |
| Income Before Tax | -25.20M | 63.67M | -31.33M | -12.73M | -40.46M |
| Income Tax Expenses | -- | 1.84M | -- | -- | -- |
| Earnings from Continuing Operations | -25.20M | 61.83M | -31.33M | -12.73M | -40.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.20M | 61.83M | -31.33M | -12.73M | -40.46M |
| EBIT | -6.58M | 85.23M | -9.96M | 7.10M | -22.10M |
| EBITDA | -6.55M | 85.26M | -9.93M | 7.12M | -22.07M |
| EPS Basic | -0.10 | 0.26 | -0.16 | -0.06 | -0.21 |
| Normalized Basic EPS | -0.06 | 0.17 | -0.10 | -0.04 | -0.13 |
| EPS Diluted | -0.10 | 0.22 | -0.16 | -0.06 | -0.21 |
| Normalized Diluted EPS | -0.06 | 0.14 | -0.10 | -0.04 | -0.13 |
| Average Basic Shares Outstanding | 251.35M | 236.68M | 200.74M | 197.55M | 196.13M |
| Average Diluted Shares Outstanding | 251.35M | 284.57M | 200.74M | 197.55M | 196.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |